Investigating the Link Between Left Ventricular Hypertrophy and Anemia in End-Stage Renal Disease: Exploring Anemia's Impact on LVH in ESRD

Fateh  Sher; Neha Fatima; Maham  Bukhari; Muhammad Arslan  Shoukat; Ayeza  Hassan; Tahreem  Afzaal; Ahmad  Shabbir; Shoaib  Zafar

doi:10.69750/dmls.01.03.028

Authors

Fateh Sher Medical officer, Al-Razi Hospital Lahore, Pakistan Author
Neha Fatima Lahore Pharmacy college, Lahore Medical and Dental College (LM&DC), Lahore, Pakistan Author
Maham Bukhari Avicenna Medical College, Lahore,Pakistan. Author
Muhammad Arslan Shoukat King Edward Medical University, Lahore,Pakistan Author
Ayeza Hassan House Officer at PAF Hospital E9 Islamabad, Pakistan Author
Tahreem Afzaal Lahore Pharmacy college, Lahore Medical and Dental College (LM&DC), Lahore, Pakistan Author
Ahmad Shabbir Department of Medicine, Nishtar Medical University, Multan, Pakistan Author
Shoaib Zafar Assistant professor,Department of pharmacy,University of health sciences(UHS),Lahore,Pakistan. Author

DOI:

https://doi.org/10.69750/dmls.01.03.028

Keywords:

End-stage renal disease, left ventricular hypertrophy, anemia, hemodialysis, echocardiography

Abstract

Background:ESRD significantly burdens healthcare systems worldwide. Its related complications, such as LVH and anemia, lead to increased morbidity and mortality. Left Ventricular Hypertrophy (LVH), which mirrors an increase in myocardial mass and wall thickness, is easily identified in patients with ESRD. Anemia, a state of low hemoglobin, increases cardiac work

Aims and Objective: To explore anemia and its association with LVH in ESRD patients on maintenance hemodialysis by detailed echocardiographic assessment and comprehensive blood analysis.

Methodology: This comparative study was carried out at a teaching hospital, namely Ghurki Teaching Hospital and a tertiary care hospital, Mayo Hospital, Lahore, Pakistan from March 2022 to April 2023. A purposive sample of 200 adults on maintenance hemodialysis with ESRD was obtained through stratified random sampling techniques and the participants were grouped based on anemia status: anemic; (hemoglobin <13g/dL in males, <12g/dL in females) or non-anemic. The data were analyzed using SPSS software (Version 26) by employing independent t-test to compare the means, chi-squared test for categorical variables, A p-value < 0. 05 was considered significant.

Results:In patients with anemia, the LVMI was significantly (P≤0.05) higher than in patients without anemia. Anemia was found to be a significant (P≤0.05) predictor of an increase in LVMI over time, indicating its role in the development of LVH.

Conclusion:The findings of present research indicated that, as shown by echocardiography, there is a substantial correlation between LVH and anemia in patients on maintenance of hemodialysis.

Downloads

Download data is not yet available.

References

Omar T, Çağdaş M, Artaç İ, Karakayalı M, İliş D, Arslan A, et al. Relationship between heart functions and anemia in end-stage renal disease patients receiving hemodialysis. Eur Res J. 2024;10(1):118-26.

Ito T, Akamatsu K. Echocardiographic manifestations in end-stage renal disease. Heart Fail Rev. 2024;29(2):465-78.

Tahara O, Dutta P. Left ventricular hypertrophy in different stages of chronic kidney disease and its correlation with anemia. J Bangladesh Coll Physicians Surg. 2024;42(1):1-7.

Li HL, Tai PH, Hwang YT, Lin SW. Five-year longitudinal study of outcomes related to end-stage kidney disease. BMC Nephrol. 2020;21:1-10.

Nguyen NN, Van Duong P, Ngoc Mai TH, Vo NH, Luong DK, Ngo TH. Left ventricular mass index in end-stage renal disease during hemodialysis versus peritoneal dialysis. Int J Clin Pract. 2023;2023:1-8.

Coimbra S, Catarino C, Faria MS, Nunes JPL, Rocha S, Valente MJ, et al. Association of leptin with left ventricular hypertrophy in end-stage kidney disease patients on dialysis. Biomedicines. 2023;11(4):1026.

Radhakrishnan A, Pickup LC, Price AM, Law JP, McGee KC, Fabritz L, et al. Coronary microvascular dysfunction and degree of anemia in end-stage renal disease. BMC Cardiovasc Disord. 2021;21(1):211.

Nardi E, Mulè G, Giammanco A, Mattina A, Geraci G, Nardi C, et al. Left ventricular hypertrophy in chronic kidney disease: diagnostic criteria comparison. Nutr Metab Cardiovasc Dis. 2021;31(1):137-44.

Io H, Muto M, Sasaki Y, Ishizaka M, Kano T, Fukuzaki H, et al. Effect of anemia treatment on LVH from pre-dialysis to maintenance dialysis in CKD patients. BMC Nephrol. 2023;24(1):74.

Alansari H, Wald R, Deva DP, Ong J, Chang LDJ, Kiaii M, et al. Cardiac MRI structure-function correlations with hemoglobin in ESRD. J Nephrol. 2021;34:1561-3.

Bhagat N, Dawman L, Naganur S, Tiewsoh K, Kumar B, Pratyusha K, et al. Effect of anemia on cardiovascular status in pediatric CKD. Clin Nutr ESPEN. 2022;47:283-7.

Maqbool S, Shafiq S, Ali S, Rehman MEU, Malik J, Lee KY. LVH and geometric patterns in CKD stage 2-5 with preserved EF: systematic review. Curr Probl Cardiol. 2023;48(4):101590.

Ali S, Umar RM, Ahmed B, Ali F, Saboor QA, Pannu FY. Effect of hemodialysis duration on left ventricular hypertrophy in CKD. Pak J Med Health Sci. 2022;16(11):238-42.

Badawy A, Nigm DA, Ezzat GM, Gamal Y. Interleukin-18 as inflammatory mediator in LVH among ESRD children. Saudi J Kidney Dis Transpl. 2020;31(6):1206-16.

Shaltout AH, Samir S, Lashin FI, Sherif MH, Aboelnasr MS. Correlation of parathyroid hormone with LV mass in ESRD on hemodialysis. Egypt Soc Nephrol Transplant J. 2021;21(3):124-9.

Rehman F, Hayat T, Fatima H, Shafiq M, Masood U, Batool R. Integrative approaches in management of diabetic foot ulcers. Dev Med Life Sci. 2024;1(2):44-52.

Lee M, Lee KJ, Lee YH, Kim D, Shin SJ, Yoon HE. Combined impact of RDW and vascular calcification on cardiovascular events in ESRD. Kidney Res Clin Pract. 2022;41(3):351-60.

Murkamilov I, Sabirov I, Fomin V, Murkamilova ZA, Yusupov F. LV myocardial changes and clinical indicators in elderly CKD. Adv Gerontol. 2022;12(1):72-8.

Raza H, Idrees B, Khan HU, Bakhtiar K, Ahmad S, Shuja A. Impact of smoking and hyperlipidemia in atherosclerotic cardiovascular disease. Pak J Health Sci. 2024;3(1):136-40.

Okamura T, Tsukamoto K, Arai H, Fujioka Y, Ishigaki Y, Koba S, et al. JAS guidelines for prevention of atherosclerotic cardiovascular diseases 2022. J Atheroscler Thromb. 2024;31(6):641-853.

Hedayatnia M, Asadi Z, Zare-Feyzabadi R, Yaghooti-Khorasani M, Ghazizadeh H, Ghaffarian-Zirak R, et al. Dyslipidemia and CVD risk in MASHAD cohort. Lipids Health Dis. 2020;19:1-11.

Damaskos C, Garmpis N, Kollia P, Mitsiopoulos G, Barlampa D, Drosos A, et al. Cardiovascular risk assessment in diabetes: update review. Curr Cardiol Rev. 2020;16(4):266-74.

Hedegaard BS, Bork CS, Kaltoft M, Klausen IC, Schmidt EB, Kamstrup PR, et al. Equivalent impact of elevated Lp(a) and familial hypercholesterolemia. J Am Coll Cardiol. 2022;80(21):1998-2010.

Mahtta D, Ramsey DJ, Al Rifai M, Nasir K, Samad Z, Aguilar D, et al. Use and adherence to aspirin and statins in premature ASCVD. JAMA Netw Open. 2020;3(8):e2011051.

Acosta S, Johansson A, Drake I. Diet/lifestyle factors and ASCVD risk: prospective cohort. Nutrients. 2021;13(11):3822.

Sun T, Chen M, Shen H, Yin P, Fan L, Chen X, et al. Predictive value of LDL/HDL ratio in coronary atherosclerosis. BMC Cardiovasc Disord. 2022;22(1):273.

Németh Á, Daróczy B, Juhász L, Fülöp P, Harangi M, Paragh G. Lipoprotein(a) and vascular diseases in familial hypercholesterolemia. Front Genet. 2022;13:849197.

Vassy JL, Lu B, Ho YL, Galloway A, Raghavan S, Honerlaw J, et al. ASCVD risk estimation in US veterans. JAMA Netw Open. 2020;3(7):e208236.

Jarab AS, Alefishat EA, Al-Qerem W, Mukattash TL, Al-Hajjeh DAM. Lipid control and predictors in Jordanian dyslipidemia patients. Int J Clin Pract. 2021;75(5):e14000.